APT Pharmaceuticals is a drug
development company focused on repurposing well-characterized
drugs for under-served populations.
APT’s initial focus
is on the pulmonary delivery of treatments for serious lung
diseases.
The company’s lead program, inhaled cyclosporine,
is in Phase III for the prevention of chronic lung transplant
rejection. For more information on the Phase III trial, visit
the study website at www.cycliststudy.com |